Definitive Contract 75D30121C10169
Award Date
1/1/21
Potential Completion Date
12/31/30
Potential Value
$11M
Federal Agency
CDC Pittsburgh
Awardee
King County
Ultimate Awardee
King County
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Seattle, WA 98104, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
22
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $5,176,985.37 cost-no-fee definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to King County, doing business as Public Health-Seattle & King County. The contract is to develop, implement, and evaluate interventions to improve identification and treatment of latent tuberculosis infection (LTBI) among high-risk non-U.S.-born populations in primary care settings. The contract is part of the TBESC 3 - Seattle and King County program and does not have a...
This is a definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Case Western Reserve University's Office of Research Administration Division, doing business as University Hospitals of Cleveland, with a ceiling value of $15,729,937.34. The contract is for tuberculosis trials and consortium services over a 10-year period of performance from January 1, 2021 to December 31, 2030. There is no set-aside designation for this award. The contract requires the vendor to...
This is a definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Siris Pharmaceutical Services LLC, a woman-owned small business, to provide tuberculosis (TB) clinical trials management support. The contract has a ceiling value of $2,395,614.70 and is a time and materials contract with a period of performance ending on September 10, 2026. The contract is designated as a total small business set-aside. This contract supports the CDC's efforts to advance TB research...
The Centers for Disease Control and Prevention (CDC) awarded a $4,455,976 cost-no-fee definitive contract to The Regents of the University of California, San Francisco (UCSF) to develop, implement, and evaluate interventions to improve latent tuberculosis infection (LTBI) identification and treatment among high-risk non-U.S.-born populations in primary care settings. This contract, known as Tuberculosis Epidemiologic Studies Consortium III (TBESC3), has a period of performance from September 29,...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Seattle Children's Hospital to conduct research on tuberculosis. The $87,790,431 contract, which has no set-aside designation, is for the "Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB)". The prime contractor is Seattle Children's Hospital, doing business as Seattle Children's Research Institute, a...
Duke University, as prime contractor, was awarded a $4.3 million delivery order against the Tuberculosis Epidemiology Studies Consortium master IDIQ by the Centers for Disease Control and Prevention. The contract calls for enrollment, preventive treatment, data collection and analysis of latent tuberculosis infection patients. Major subcontractors include Atrium Health and Vanderbilt University, which will assist with performance of the clinical work. The goal of the project appears to be...
This federal contract, valued at $3,752,362.88, was awarded by the Centers for Disease Control and Prevention (CDC) to the University of North Texas Health Science Center at Fort Worth (UNTHSC) to conduct a comparative study on tuberculosis (TB) testing methods. The contract is part of the Tuberculosis Epidemiology Studies Consortium, an indefinite delivery contract, and does not have a set-aside designation. Under this task order, UNTHSC is evaluating the performance of the tuberculin skin test...
This is a definitive cost-reimbursement contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to the Denver Health and Hospital Authority (Denver Health) for the Tuberculosis Trials Consortium (TBTC). The contract, which does not have a set-aside designation, has a potential value of $311,831.31 and a completion date of October 9, 2022. As a 555-bed academic health system and the region's only Level I trauma center, Denver Health...
This federal contract was awarded by the Centers for Disease Control and Prevention (CDC) to Weill Medical College of Cornell University, doing business as Joan & Sanford I Weill Medical College of Cornell University, for tuberculosis trials and consortium services. The 10-year, $5,917,206.24 contract is a definitive, cost-no-fee contract that does not have a set-aside designation. The contract supports clinical trials and research on the treatment, diagnosis, and prevention of tuberculosis,...
The Centers for Disease Control and Prevention awarded a $32,145.69 firm fixed price delivery order contract to the University of Washington School of Medicine to provide testing for tuberculosis as part of Task 02 for the National Health and Nutrition Examination Survey. Performance will take place in Seattle, Washington by January 14, 2021. As the parent organization of the prime awardee, the University of Washington will also support this work. No set-aside designation was used for this...